Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listTUMOR NECROSIS FACTOR

TUMOR NECROSIS FACTOR

  • Molecular Weight: 0
  • MDL number: MFCD00080185
  • Update Date: 2023-03-21 13:45:01

What is TUMOR NECROSIS FACTOR?

Description

The importance of TNF is highlighted by its discovery in diseases and multiple key biological processes including immune homeostasis, cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. TNF was originally found in mouse serum after the intravenous injection of bacterial endotoxin into mice primed with a viable Mycobacterium bovis Bacillus Calmette-Guerin (BCG) strain; it was shown to cause the necrosis of tumors. Human TNF cDNA and its mRNA were identified in 4β-phorbol 12β-myristate 13α-acetate (PMA)-stimulated HL-60, a monocyte-like cell line derived from a promyelocytic leukemia. The biosynthesis of TNF was clarified by the identification of the cell surface precursor transmembrane form and its processing enzyme, TNF-α-converting enzyme (TACE).

Physical properties

Mr. 26,000 (tmTNF), 17,000 (sTNF). pI 5.8 (human sTNF). TNF is soluble in water. TNF is stable in plasma and serum for 8 h at room temperature and for 24 h at 4°C, -20°C, or -70°C.

General Description

The TNFs (Etanercept, Enbrel) are members of a family ofcytokines that are produced primarily in the innate immunesystem by activated mononuclear phagocytes. Etanercept is a dimeric fusion protein consisting of the extracellularligand-binding portion of the human 75-kDa (p75)TNF receptor (TNFR) linked to the Fc portion of human isotypeIgG1. The Fc component of etanercept contains the CH2domain, the CH3 domain, and the hinge region, but not theCH1 domain of IgG1. These regions are responsible for thebiological effects of immunoglobulins. Each etanerceptmolecule binds specifically to two TNF molecules in the synovialfluid of rheumatoid arthritis patients. It is equally efficaciousat blocking TNFα and TNFβ. The drug is indicatedfor reducing signs and symptoms and inhibiting the progressionof structural damage in patients with moderately toseverely active rheumatoid arthritis. Etanercept is also indicatedfor reducing signs and symptoms of moderately toseverely active polyarticular-course juvenile rheumatoidarthritis in patients 4 years of age and older who have had aninadequate response to one or more disease-modifying antirheumaticdrugs (DMARDS). Etanercept is also indicatedfor reducing signs and symptoms of active arthritis in patientswith psoriatic arthritis.

Clinical Use

Mutations in the TNFRSF1A1 gene are associated with autosomal dominant autoinflammatory disorder, called TNF receptor-associated periodic syndrome (TRAPS); this was first described as familial Hibernian fever (FHF). Polymorphisms in TNFRSF1B have also been identified in some patients with familial rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, ulcerative colitis, and immune-related conditions such as graft versus host disease associated with scleroderma risk. Some polymorphisms of the TNF gene promoter are observed in patients with systemic lupus erythematosus (SLE), rheumatoid arthritis, and ankylosing spondylitis.

Structure and conformation

TNF exists in two forms: a type II transmembrane protein (tmTNF) and a mature soluble protein (sTNF) . The TNF protein is first produced as tmTNF on the cell surface. tmTNF is enzymatically cleaved at its Ala76-Val77 site by TACE and is released as sTNF. sTNF forms a noncovalently bound homotrimer that is at least eight-fold more active than the monomer. The TNF monomer has 10 antiparallel β-sheets and exhibits a “jelly-roll” topology. Individual subunits form the trimer by an edge-to-face interaction of β-sheets. sTNF contains one disulfide bond (Cys69-Cys101), which plays a role in its biological functions.
Structure of TNF

Properties of TUMOR NECROSIS FACTOR

storage temp.  -20°C

Safety information for TUMOR NECROSIS FACTOR

Computed Descriptors for TUMOR NECROSIS FACTOR

You may like

  • Anti-TSG6 antibody produced in rabbit CAS
    Anti-TSG6 antibody produced in rabbit CAS
    View Details
  • Dimethyl [2-oxo-3-[3-(trifluoromethyl)phenoxy]propyl]phosphonate 99%
    Dimethyl [2-oxo-3-[3-(trifluoromethyl)phenoxy]propyl]phosphonate 99%
    54094-19-8
    View Details
  • 85-81-4 99%
    85-81-4 99%
    85-81-4
    View Details
  • 208111-98-2 (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-4-[3-(trifluoromethyl)phenoxy]-1-buten- 1-yl]-2H-cyclopenta[b]furan-2-one 99%
    208111-98-2 (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-4-[3-(trifluoromethyl)phenoxy]-1-buten- 1-yl]-2H-cyclopenta[b]furan-2-one 99%
    208111-98-2
    View Details
  • 2033-24-1 99%
    2033-24-1 99%
    2033-24-1
    View Details
  • Meldrums acid 2033-24-1 99%
    Meldrums acid 2033-24-1 99%
    2033-24-1
    View Details
  • Cyaclopentane carboxylic acid 99%
    Cyaclopentane carboxylic acid 99%
    3400-45-1
    View Details
  • 2-Aminopyridine 504-29-0 99%
    2-Aminopyridine 504-29-0 99%
    504-29-0
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.